Displaying items by tag: division of hematology and oncology

When Cameron Monistere was diagnosed with cancer right before his senior year of college and final season as an Auburn University cheerleader, he acted fast. With the help of UAB experts, Monistere is now cancer-free and using his story to raise awareness about men’s health.
Direct reprogramming is a potential therapy for heart attack patients. In vitro, TBX20 improved contractility and mitochondrial function of reprogrammed heart muscle cells.
UAB’s CAR T-cell therapy cured stage 4 lymphoma with the help of the patient’s resilience and the doctor’s timely diagnosis and treatment.
Results published in the Journal of Alzheimer’s Disease show patients with one cancer diagnosis were less likely to develop dementia and had an overall slower cognitive decline than patients with no history of cancer.  

Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.

At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.

The largest registry of U.S. children with cancer who were diagnosed with COVID-19 found an increased risk of having severe infection and having their cancer therapy modified because of COVID, underscoring the urgency of vaccinations for these children, the authors say.

UAB’s Julie Kanter, M.D., says statewide surveillance programs for sickle cell disease can help facilitate progress to improve outcomes.
Treating blood disorders and cancers cannot be done alone. It requires the strong will of a patient, the support of family, and the compassion and expertise of a world-renowned health care team, like those with the O’Neal Comprehensive Cancer Center at UAB’s Bone Marrow Transplantation and Cell Therapy program.
Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.
Tagged under
Page 1 of 6